Pfizer announced this morning more promising data from a phase 2/3 study of its oral antiviral medication, Paxlovid. The pill reduced COVID-19 hospitalization or death by 89% if taken within 3 days of symptom onset, and 88% if taken within 5 days, and in vitro studies indicated the pill could work against the Omicron variant."This news provides further corroboration that our oral antiviral candidate, if authorized or approved, could have a meaningful impact on the lives of many, as the data further support the efficacy of Paxlovid in reducing hospitalization and death and show a substantial decrease in viral load," said Albert Bourla, the CEO of Pfizer in a press release."Emerging variants of concern, like Omicron, have exacerbated the need